LRCX vs NTLA · P/E 71, rev $23.23B vs rev $22.7M
Lam Research Corp (LRCX) versus Intellia Therapeutics Inc (NTLA) — a side-by-side from cached financials, not a winner call.
Lam Research Corp (LRCX) is a semiconductor equipment & materials company listed on NASDAQ. It is led by Timothy M. Archer.
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
Latest reported LRCX revenue for 2026-06-28 was $23.23B. Net income was $7.27B. LRCX currently screens at market cap $467.94B and trailing P/E 70.9.
Latest reported NTLA revenue for 2026-06-30 was $22.7M. Net income was -$202.9M. Revenue was up 50.9% from 2026-03-31 to 2026-06-30. NTLA currently screens at market cap $1.19B.
LRCX currently screens at market cap $467.94B and trailing P/E 70.9. NTLA currently screens at market cap $1.19B.
Not investment advice. Open the LRCX and NTLA stock pages for the full models.
Not investment advice.